ITMCTR2000003235Not yet recruiting未知
A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia
Wuhan Hospital Of Traditional Chinese and Western Medicine (Wuhan 1st Hospital)0 sitesStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional study
Eligibility Criteria
- Ages
- 18 to 70 (—)
- Sex
- All
Inclusion Criteria
- •1. Meet the convalescence of COVID-19 diagnostic criteria;
- •2. Short breath, hyperhidrosis, dry cough, chest distress, palpitation and other clinical discomfort symptoms of lung and heart function decline, in which 3 symptoms appear at the same time, or the visual analogue score of single symptom (VAS) >=4 points;
- •3. Patients who were discharged for more than 2 weeks were cured;
- •4. Aged 18-70 years old;
- •5. Sign informed consent.
Exclusion Criteria
- •1. Because of other reasons, such as shortness of breath, hyperhidrosis, dry cough, chest distress, palpitation, etc;
- •2. Patients with difficulty in taking drugs orally due to basic diseases;
- •3. There are serious basic diseases that affect survival, including uncontrolled clinically significant heart, lung, kidney, digestion, blood disease, neuropsychiatric disease, immune disease, metabolic disease, malignant tumor, severe malnutrition, etc;
- •4. Allergic constitution, allergic to drugs involved in the treatment plan;
- •5. Pregnant or lactating women;
- •6. Those who can't cooperate in mental state, suffer from mental disease, have no self-control and can't express clearly;
- •7. Those who are participating in other clinical trials;
- •8. According to the judgment of the researchers, there will be patients with complicated enrollment or poor compliance that affect the efficacy and safety evaluation.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurin for the prevention of arterial events in patients with vEDS confirmed with COL3A1 mutationsvascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutationsMedDRA version: 20.0Level: PTClassification code 10014316Term: Ehlers-Danlos syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-006574-23-NLAytu BioPharma, Inc.260
Active, not recruiting
Phase 1
A clinical study to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent, after surgical treatment and/or Chronic Thromboembolic Pulmonary Hypertension (CTEPH).Chronic Thromboembolic Pulmonary Hypertension, inoperable or persistent/recurrentMedDRA version: 21.1Level: LLTClassification code 10068739Term: Chronic thromboembolic pulmonary hypertensionSystem Organ Class: 100000004855EUCTR2018-002823-41-ATActelion Pharmaceuticals Ltd280
Active, not recruiting
Phase 1
EVOLVE-FD: Effects of EVOLocumab VErsus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids in patients with Familial DysbetalipoproteinemiaFamilial DysbetalipoproteinemiaEUCTR2018-003476-12-NLniversity Medical Center Utrecht30
Active, not recruiting
Phase 1
Efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failureAcute heart failureEUCTR2013-001498-25-ATovartis Pharma Services AG6,800
Active, not recruiting
Phase 1
QGE031 Phase 2b dose-finding study to investigate efficacy and safety in adolescents with CSChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2017-004207-52-EEovartis Pharma AG48